Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: Poor treatment outcomes of visceral leishmaniasis (VL) are responsible for the high mortality rate of this condition in resource-limited settings such as Ethiopia. This study aimed to identify the proportion of poor VL treatment outcomes in northwest Ethiopia and to evaluate the determinants associated with poor outcomes. METHODS: A hospital-based retrospective study was conducted among 595 VL patients who were admitted to Kahsay Abera Hospital in northwest Ethiopia from October 2010 to April 2013. Data were entered into Epi Info version 7.0 and exported to SPSS version 20 for analysis. Bivariate and multivariate logistic regression models were fitted to identify the determinants of VL treatment outcomes. Adjusted odds ratio (aORs) with 95% confidence intervals (CIs) were used, and p-values <0.05 were considered to indicate statistical significance. RESULTS: The proportion of poor treatment outcomes was 23.7%. Late diagnosis (≥29 days) (aOR, 4.34; 95% CI, 2.22 to 8.46), severe illness at admission (inability to walk) (aOR, 1.63; 95% CI, 1.06 to 2.40) and coinfection with VL and human immunodeficiency virus (HIV) (aOR, 2.72; 95% CI, 1.40 to 5.20) were found to be determinants of poor VL treatment outcomes. CONCLUSIONS: Poor treatment outcomes, such as death, treatment failure, and non-adherence, were found to be common. Special attention must be paid to severely ill and VL/HIV-coinfected patients. To improve VL treatment outcomes, the early diagnosis and treatment of VL patients is recommended.
Abstract
OBJECTIVES: Poor treatment outcomes of visceral leishmaniasis (VL) are responsible for the high mortality rate of this condition in resource-limited settings such as Ethiopia. This study aimed to identify the proportion of poor VL treatment outcomes in northwest Ethiopia and to evaluate the determinants associated with poor outcomes. METHODS: A hospital-based retrospective study was conducted among 595 VL patients who were admitted to Kahsay Abera Hospital in northwest Ethiopia from October 2010 to April 2013. Data were entered into Epi Info version 7.0 and exported to SPSS version 20 for analysis. Bivariate and multivariate logistic regression models were fitted to identify the determinants of VL treatment outcomes. Adjusted odds ratio (aORs) with 95% confidence intervals (CIs) were used, and p-values <0.05 were considered to indicate statistical significance. RESULTS: The proportion of poor treatment outcomes was 23.7%. Late diagnosis (≥29 days) (aOR, 4.34; 95% CI, 2.22 to 8.46), severe illness at admission (inability to walk) (aOR, 1.63; 95% CI, 1.06 to 2.40) and coinfection with VL and human immunodeficiency virus (HIV) (aOR, 2.72; 95% CI, 1.40 to 5.20) were found to be determinants of poor VL treatment outcomes. CONCLUSIONS: Poor treatment outcomes, such as death, treatment failure, and non-adherence, were found to be common. Special attention must be paid to severely ill and VL/HIV-coinfected patients. To improve VL treatment outcomes, the early diagnosis and treatment of VL patients is recommended.
참고문헌 (21)
- van Griensven J, "Visceral leishmaniasis and HIV coinfection: time for concerted action", PLoS Negl Trop Dis, 8, pp.3023~ (2014)
- Perry D, "Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011", Am J Trop Med Hyg, 88, pp.778~784 (2013)
- Huda MM, "Visceral leishmaniasis-associated mortality in Bangladesh: a retrospective cross-sectional study", BMJ Open, 4, pp.005408~ (2014)
- Jarvis JN, "Clinical aspects of visceral leishmaniasis in HIV infection", Curr Opin Infect Dis, 26, pp.1~9 (2013)
- Mourão MV, "Parasite load and risk factors for poor outcome among children with visceral leishmaniasis", Mem Inst Oswaldo Cruz, 109, pp.147~153 (2014)
- Hotez PJ, "Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden", PLoS Negl Trop Dis, 3, pp.412~ (2009)
- van den Bogaart E, "Concomitant malaria among visceral leishmaniasis in-patients from Gedarif and Sennar States, Sudan: a retrospective case-control study", BMC Public Health, 13, pp.332~ (2013)
- Alvar J, "Leishmaniasis worldwide and global estimates of its incidence", PLoS One, 7, pp.35671~ (2012)
- Hurissa Z, "Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia", Trop Med Int Health, 15, pp.848~855 (2010)
- Endris M, "Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia", Biomed Res Int, 2014, pp.361058~ (2014)
- Argaw D, "Risk factors for visceral leishmaniasis among residents and migrants in Kafta-Humera, Ethiopia", PLoS Negl Trop Dis, 7, pp.2543~ (2013)
- Atia AM, "Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan", Trop Med Int Health, 20, pp.1674~1684 (2015)
- Federal Ministry Health of Ethiopia, "Guidlines for diagnosis, treatment and prevention of leishmaniasis in Ethiopia", pp.1~88 (2013), Ministry of Health
- Sinha PK, "Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India", Am J Trop Med Hyg, 83, pp.357~364 (2010)
- Lyons S, "Visceral leishmaniasis and HIV in Tigray, Ethiopia", Trop Med Int Health, 8, pp.733~739 (2003)
- Santos MA, "Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis", Rev Soc Bras Med Trop, 35, pp.629~633 (2002)
- Diro E, "High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia", pp.2875~ (2014), PLoS Negl Trop Dis
- Llanos-Cuentas A, "Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru", Clin Infect Dis, 46, pp.223~231 (2008)
- Kajaia M, "Risk factors for relapse of visceral leishmaniasis in Georgia", Trop Med Int Health, 16, pp.186~192 (2011)
- Collin S, "Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan", Clin Infect Dis, 38, pp.612~619 (2004)
- ter Horst R, "Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome", Clin Infect Dis, 46, pp.1702~1709 (2008)